TrialFuture oncology (London, England)2025

EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).

Maeve A Hennessy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.